© Foto: Sascha Lotz/dpa
© Foto: Sascha Lotz/dpa
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10:46 | DB says Roche could challenge obesity drug leaders Eli Lilly, Novo Nordisk | ||
09:46 | LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval | ||
Do | Eli Lilly falls on a rival's obesity study - plus, we're removing 3 stocks from our watchlist | ||
Do | In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1 | ||
Do | Lilly's once-weekly insulin matches daily shots in late-stage tests |